PlainRecalls
FDA Drug Critical Class I Terminated

Limbrel250 (flavocoxid and citrated zinc bisglycinate) 250 mg/50 mg capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-605-16.

Reported: February 21, 2018 Initiated: January 26, 2018 #D-0346-2018

Product Description

Limbrel250 (flavocoxid and citrated zinc bisglycinate) 250 mg/50 mg capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-605-16.

Reason for Recall

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Details

Units Affected
4,006 bottles
Distribution
Nationwide in the USA.
Location
Scottsdale, AZ

Frequently Asked Questions

What product was recalled?
Limbrel250 (flavocoxid and citrated zinc bisglycinate) 250 mg/50 mg capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-605-16.. Recalled by Primus Pharmaceuticals, Inc.. Units affected: 4,006 bottles.
Why was this product recalled?
Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 21, 2018. Severity: Critical. Recall number: D-0346-2018.